BUSINESSFINANCIAL TIMES WORLD
AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough
AstraZeneca and Bristol-Myers Squibb suggest that larger financial resources enable greater investment in potential blockbuster drugs. The article highlights the advantage of enlarged balance sheets in pharmaceutical development.
Mentioned
Related Signal
Adjacent reporting
- AstraZeneca said to have explored Bristol Myers merger
- AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
- AstraZeneca Said to Have Explored Bristol Myers Merger
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
- STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger